Abstract
New World cutaneous leishmaniasis (CL) is endemic in many countries of Latin America, including French Guiana 1 . While pentamidine is the first-line treatment against Leishmania guyanensis in this territory 2 , pentavalent antimonials such as meglumine antimoniate (MA) are recommended in case of L. braziliensis or pentamidine-resistant strains of other species 2 . Liposomal amphotericin B (L-AmB) (Ambisome ®) is widely used against fungi and visceral leishmaniasis 3 . However, data concerning its efficacy in New World CL are scarce and contradictory 4-7 . Due to a shortage in MA, the Cayenne Hospital started using L-AmB as an alternative in 2015. We conducted a retrospective study to compare efficacy and safety of L-AmB and MA in patients treated for CL.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
